- Home
- ELVA vs ACRS Comparison
ELVA vs ACRS Comparison
Compare ELVA & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVA
- ACRS
- Stock Information
- Founded
- ELVA 1996
- ACRS 2012
- Country
- ELVA Canada
- ACRS United States
- Employees
- ELVA N/A
- ACRS N/A
- Industry
- ELVA
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- ELVA
- ACRS Health Care
- Exchange
- ELVA Nasdaq
- ACRS Nasdaq
- Market Cap
- ELVA 125.5M
- ACRS 137.5M
- IPO Year
- ELVA N/A
- ACRS 2015
- Fundamental
- Price
- ELVA $3.55
- ACRS $1.53
- Analyst Decision
- ELVA Strong Buy
- ACRS Strong Buy
- Analyst Count
- ELVA 5
- ACRS 8
- Target Price
- ELVA $6.10
- ACRS $9.71
- AVG Volume (30 Days)
- ELVA 108.9K
- ACRS 747.8K
- Earning Date
- ELVA 08-12-2025
- ACRS 08-06-2025
- Dividend Yield
- ELVA N/A
- ACRS N/A
- EPS Growth
- ELVA N/A
- ACRS N/A
- EPS
- ELVA N/A
- ACRS N/A
- Revenue
- ELVA $48,016,000.00
- ACRS $17,777,000.00
- Revenue This Year
- ELVA $55.29
- ACRS N/A
- Revenue Next Year
- ELVA $63.69
- ACRS $11.66
- P/E Ratio
- ELVA N/A
- ACRS N/A
- Revenue Growth
- ELVA N/A
- ACRS N/A
- 52 Week Low
- ELVA $1.67
- ACRS $1.05
- 52 Week High
- ELVA $3.71
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- ELVA 67.98
- ACRS 58.82
- Support Level
- ELVA $3.07
- ACRS $1.45
- Resistance Level
- ELVA $3.71
- ACRS $1.59
- Average True Range (ATR)
- ELVA 0.17
- ACRS 0.10
- MACD
- ELVA 0.03
- ACRS 0.01
- Stochastic Oscillator
- ELVA 78.08
- ACRS 72.09
About ELVA Electrovaya Inc.
Electrovaya Inc designs develop and manufacture proprietary lithium-ion batteries, battery systems, and battery-related products for energy storage, clean electric transportation and other specialized applications. It is a technology-focused company with extensive IP. The company generates revenue from the sale of batteries and battery systems. Business operations are segmented based on large format batteries and others. This technology offers enhanced safety and battery longevity. Geographically it earns key revenue from the United States.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.